Vor Bio upgraded to Buy from Hold at Stifel

Stifel analyst Stephen Willey upgraded Vor Bio (VOR) to Buy from Hold with a $55 price target The firm notes that its multiple recent management meetings have turned it “incrementally more-positive” on telitacicept prospects across a diverse spectrum of autoimmune diseases, the analyst tells investors in a research note. Telitacicept, which already has three regulatory approvals and two planned regulatory submissions in China, is poised to potentially emerge as a best-in-class dual BAFF/APRIL antagonist, and the firm believes the requisite translation of this success to ongoing myasthenia gravis and aspiring global Phase 3 trials represents attractive biological/clinical and financial risk, the firm added.